Antibiotic resistance is a bacterial defense mechanism against antibiotics. It can rapidly spread from one bacterium to another. This makes antibiotics increasingly ineffective.
Detailed description
The level of resistances against antibiotics is rising. This is a great challenge for physicians and scientists. Scientists within the DZIF research field “Healthcare-associated and Antibiotic-resistant bacterial Infections” aim to develop new strategies against the development and spread of resistance.
More about “Antibiotic resistance”
Please use image only in connection with the press release.
Every year at least 700,000 people die as a result of infection with antibiotic-resistant bacteria—a figure which according to WHO forecasts could rise to ten million people by 2050 without new
The incubator INCATE (INCubator for Antibacterial Therapies in Europe) was founded by a consortium of academic institutions—including the German Center for Infection Research (DZIF)—and industrial
The INCubator for Antibacterial Therapies in Europe, INCATE, aims to support innovators in the early stages of developing therapies in the field of antimicrobial resistance. The German Center for
Please use this graphic only in connection to this press release.
Colistin is a last-line reserve antibiotic for the treatment of infections caused by extremely multidrug-resistant (XDR) Gram-negative bacteria. The recent emergence and global spread of the mobile
Scanning electron micrograph: C. difficile cells were provided by Nicole Metzendorf from the Department of Microbial Physiology and Molecular Biology, Institute of Microbiology, and imaged by Rabea Schlüter, Imaging Center of the Department of Biology, University of Greifswald, Germany.
Please use this image only in connection with this press release.
Infections with the bacterium Clostridioides difficile (C. difficile for short) frequently recur due to permanent stages remaining in the intestine. A drug that also effectively combats the permanent
The pathogenHelicobacter pylori, which is responsible for highly prevalent diseases such as gastric ulcers or cancer, has a weak spot that could be used to produce new drugs. This was discovered by a
In many infections, even proper antibiotic treatment does not lead to the expected therapeutic success. In the case of treatment with antibiotics, the doctor usually first decides which antibiotic to prescribe based on the type of infection. If resistance to the antibiotic already prescribed is ...
The antibiotic Bedaquiline (BDQ) was approved in 2014 specifically for the treatment of multidrug-resistant (MDR) tuberculosis (TB) and has since been an important component of successful MDR TB
We still do not understand exactly how antibiotics kill bacteria. However, this understanding is necessary if we want to develop new antibiotics. And that is precisely what is urgently needed, because
Prof. Ernst's working group operates at the interface of molecular microbiology, genomics, epidemiology and chemical biology to identify, investigate, and target unrecognised pathways in persistent and multidrug-resistant infections. To this end, the group conducts mechanistic investigations ...
